Display Settings:

Format

Send to:

Choose Destination
    Mol Immunol. 2007 Sep;44(16):3858-61.

    Established and new treatments for hereditary angioedema: An update.

    Source

    Department of Internal Medicine, University of Milan, L. Sacco Hospital, Via G.B. Grassi 74, 20157 Milan, Italy. Marco.Cicardi@unimi.it

    Abstract

    Hereditary angioedema (HAE) is due to inherited deficiency of C1-inhibitor (C1-INH) and causes localized swelling that may be life-threatening when it affects the larynx. Replacement therapy with plasma derived C1-INH has been the principal life saving treatment for more than 20 years in several European countries. Nevertheless, it is not licensed in U.S. and even in Europe it is mostly supplied on a named patient basis. In the last 5 years, controlled clinical trials with four products (plasma derived C1-INH, the enzyme inhibitor Dx-88, the receptor antagonist Icatibant and a recombinant form of human C1-INH) have been performed or initiated in order to demonstrate their efficacy in reverting symptoms of HAE. Here we review the characteristics of these products and the current situation of the trials.

    PMID:
    17768103
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk